Marker Therapeutics, Inc. (MRKR)
USD 0.96
(-4.28%)
USD 0.96
(-4.28%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 17.89 Million USD | -80.81% |
| 2022 | 38.95 Million USD | -4.32% |
| 2021 | 40.71 Million USD | 38.73% |
| 2020 | 29.35 Million USD | 29.07% |
| 2019 | 22.74 Million USD | -84.67% |
| 2018 | 148.37 Million USD | 1192.48% |
| 2017 | 11.48 Million USD | 38.97% |
| 2016 | 8.26 Million USD | 34.13% |
| 2015 | 6.15 Million USD | 82.71% |
| 2014 | 3.37 Million USD | 26.52% |
| 2013 | 2.66 Million USD | -51.36% |
| 2012 | 5.47 Million USD | 107.74% |
| 2011 | 2.63 Million USD | -33.1% |
| 2010 | 3.94 Million USD | -6.01% |
| 2009 | 4.19 Million USD | 179.48% |
| 2008 | 1.5 Million USD | -40.25% |
| 2007 | 2.51 Million USD | 182.73% |
| 2006 | 888.25 Thousand USD | -10.24% |
| 2005 | 989.55 Thousand USD | -63.12% |
| 2004 | 2.68 Million USD | -53.57% |
| 2003 | 5.77 Million USD | 152.94% |
| 2002 | 2.28 Million USD | 501.46% |
| 2001 | 379.86 Thousand USD | -74.5% |
| 2000 | 1.48 Million USD | 29.93% |
| 1999 | 1.14 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.79 Million USD | -5.04% |
| 2024 Q2 | 3.47 Million USD | -8.33% |
| 2023 FY | 17.89 Million USD | -54.07% |
| 2023 Q2 | 4.13 Million USD | -51.66% |
| 2023 Q1 | 8.55 Million USD | -13.75% |
| 2023 Q4 | 3.99 Million USD | 24.82% |
| 2023 Q3 | 3.2 Million USD | -22.59% |
| 2022 Q3 | 5.82 Million USD | -37.21% |
| 2022 Q1 | 9.79 Million USD | -11.01% |
| 2022 Q2 | 9.27 Million USD | -5.26% |
| 2022 Q4 | 9.91 Million USD | 70.18% |
| 2022 FY | 38.95 Million USD | -4.32% |
| 2021 Q3 | 10.02 Million USD | -8.12% |
| 2021 FY | 40.71 Million USD | 38.73% |
| 2021 Q1 | 8.78 Million USD | 3.2% |
| 2021 Q2 | 10.9 Million USD | 24.24% |
| 2021 Q4 | 11 Million USD | 9.8% |
| 2020 Q2 | 6.82 Million USD | 2.72% |
| 2020 Q1 | 6.64 Million USD | 19.16% |
| 2020 FY | 29.35 Million USD | 29.07% |
| 2020 Q3 | 7.37 Million USD | 8.09% |
| 2020 Q4 | 8.5 Million USD | 15.35% |
| 2019 Q4 | 5.57 Million USD | -1.41% |
| 2019 Q2 | 5.87 Million USD | 4.17% |
| 2019 Q1 | 5.63 Million USD | -95.85% |
| 2019 FY | 22.74 Million USD | -84.67% |
| 2019 Q3 | 5.65 Million USD | -3.73% |
| 2018 Q2 | 4.87 Million USD | 52.61% |
| 2018 Q1 | 3.19 Million USD | 19.29% |
| 2018 FY | 148.37 Million USD | 1192.48% |
| 2018 Q4 | 135.87 Million USD | 2968.19% |
| 2018 Q3 | 4.42 Million USD | -9.25% |
| 2017 Q1 | 2.41 Million USD | 51.88% |
| 2017 Q4 | 2.68 Million USD | -32.81% |
| 2017 FY | 11.48 Million USD | 38.97% |
| 2017 Q3 | 3.98 Million USD | 66.7% |
| 2017 Q2 | 2.39 Million USD | -0.98% |
| 2016 Q4 | 1.59 Million USD | -41.53% |
| 2016 Q3 | 2.72 Million USD | 24.03% |
| 2016 Q1 | 1.75 Million USD | -22.22% |
| 2016 Q2 | 2.19 Million USD | 25.13% |
| 2016 FY | 8.26 Million USD | 34.13% |
| 2015 Q2 | 1.13 Million USD | 10.69% |
| 2015 Q4 | 2.25 Million USD | 29.74% |
| 2015 Q1 | 1.02 Million USD | 160.79% |
| 2015 FY | 6.15 Million USD | 82.71% |
| 2015 Q3 | 1.73 Million USD | 52.72% |
| 2014 Q4 | 394.24 Thousand USD | -71.51% |
| 2014 Q3 | 1.38 Million USD | 189.25% |
| 2014 Q2 | 478.37 Thousand USD | -59.69% |
| 2014 FY | 3.37 Million USD | 26.52% |
| 2014 Q1 | 1.18 Million USD | -1.92% |
| 2013 FY | 2.66 Million USD | -51.36% |
| 2013 Q4 | 1.2 Million USD | 316.72% |
| 2013 Q3 | 290.33 Thousand USD | -24.38% |
| 2013 Q2 | 383.91 Thousand USD | -45.61% |
| 2013 Q1 | 705.83 Thousand USD | -44.89% |
| 2012 FY | 5.47 Million USD | 107.74% |
| 2012 Q2 | 3.03 Million USD | 428.29% |
| 2012 Q1 | 575.05 Thousand USD | 17.67% |
| 2012 Q4 | 1.28 Million USD | 120.1% |
| 2012 Q3 | 581.92 Thousand USD | -80.84% |
| 2011 FY | 2.63 Million USD | -33.1% |
| 2011 Q2 | 603.31 Thousand USD | -18.87% |
| 2011 Q4 | 488.7 Thousand USD | -39.0% |
| 2011 Q1 | 743.64 Thousand USD | -76.51% |
| 2011 Q3 | 801.19 Thousand USD | 32.8% |
| 2010 Q2 | 1.17 Million USD | -19.63% |
| 2010 Q1 | 1.46 Million USD | -61.12% |
| 2010 FY | 3.94 Million USD | -6.01% |
| 2010 Q3 | 3.41 Million USD | 190.31% |
| 2010 Q4 | 3.16 Million USD | -7.31% |
| 2009 Q3 | 1.11 Million USD | 62.67% |
| 2009 Q2 | 683.34 Thousand USD | 138.6% |
| 2009 Q4 | 3.76 Million USD | 238.71% |
| 2009 Q1 | 286.4 Thousand USD | -30.92% |
| 2009 FY | 4.19 Million USD | 179.48% |
| 2008 Q3 | 132.83 Thousand USD | -72.93% |
| 2008 FY | 1.5 Million USD | -40.25% |
| 2008 Q2 | 490.72 Thousand USD | 6.16% |
| 2008 Q1 | 462.25 Thousand USD | -47.51% |
| 2008 Q4 | 414.61 Thousand USD | 212.13% |
| 2007 Q1 | 283.32 Thousand USD | 3.43% |
| 2007 Q3 | 502.38 Thousand USD | -40.54% |
| 2007 Q4 | 880.66 Thousand USD | 75.3% |
| 2007 Q2 | 844.96 Thousand USD | 198.23% |
| 2007 FY | 2.51 Million USD | 182.73% |
| 2006 Q2 | 162.22 Thousand USD | 33.12% |
| 2006 Q3 | 330.23 Thousand USD | 103.57% |
| 2006 Q4 | 273.93 Thousand USD | -17.05% |
| 2006 FY | 888.25 Thousand USD | -10.24% |
| 2006 Q1 | 121.85 Thousand USD | -36.96% |
| 2005 Q3 | 311.63 Thousand USD | -32.21% |
| 2005 Q4 | 193.29 Thousand USD | -37.97% |
| 2005 Q2 | 459.68 Thousand USD | 174.46% |
| 2005 Q1 | 167.48 Thousand USD | -84.68% |
| 2005 FY | 989.55 Thousand USD | -63.12% |
| 2004 Q2 | 521.32 Thousand USD | -22.15% |
| 2004 Q1 | 669.65 Thousand USD | -74.54% |
| 2004 Q4 | 1.09 Million USD | 173.73% |
| 2004 Q3 | 399.41 Thousand USD | -23.39% |
| 2004 FY | 2.68 Million USD | -53.57% |
| 2003 Q1 | 874.64 Thousand USD | -23.51% |
| 2003 Q2 | 1.28 Million USD | 46.39% |
| 2003 Q3 | 993.14 Thousand USD | -22.43% |
| 2003 FY | 5.77 Million USD | 152.94% |
| 2003 Q4 | 2.63 Million USD | 164.89% |
| 2002 Q2 | 992.27 Thousand USD | 363.02% |
| 2002 FY | 2.28 Million USD | 501.46% |
| 2002 Q4 | 1.14 Million USD | 109.19% |
| 2002 Q3 | 546.59 Thousand USD | -44.92% |
| 2002 Q1 | 214.3 Thousand USD | 440.8% |
| 2001 FY | 379.86 Thousand USD | -74.5% |
| 2001 Q1 | 409.95 Thousand USD | 24.38% |
| 2001 Q2 | 11.43 Thousand USD | -97.21% |
| 2001 Q3 | 56.74 Thousand USD | 396.02% |
| 2001 Q4 | 39.62 Thousand USD | -30.16% |
| 2000 Q1 | 305.35 Thousand USD | 0.0% |
| 2000 Q3 | 464.27 Thousand USD | 44.76% |
| 2000 Q2 | 320.72 Thousand USD | 5.03% |
| 2000 Q4 | 329.59 Thousand USD | -29.01% |
| 2000 FY | 1.48 Million USD | 29.93% |
| 1999 FY | 1.14 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 93.499% |
| Alkermes plc | 996.24 Million USD | 98.204% |
| Agenus Inc. | 78.18 Million USD | 77.115% |
| Aptorum Group Limited | 10.56 Thousand USD | -169240.441% |
| Ardelyx, Inc. | 169.93 Million USD | 89.471% |
| Dyadic International, Inc. | 9.15 Million USD | -95.489% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 19.595% |
| Lantern Pharma Inc. | 17.87 Million USD | -0.084% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -165.785% |
| Novavax, Inc. | 779.12 Million USD | 97.704% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 77.927% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 78.232% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 7.859% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 39.565% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 66.321% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 95.298% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 26.388% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 52.752% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 41.853% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 78.879% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2.495% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 89.377% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 45.308% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 88.802% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.006% |
| AlloVir, Inc. | 180.93 Million USD | 90.111% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 95.986% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 39.719% |
| Bicycle Therapeutics plc | 216.92 Million USD | 91.752% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 89.591% |
| ChromaDex Corporation | 56.37 Million USD | 68.264% |
| Chimerix, Inc. | 93.38 Million USD | 80.841% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -28.634% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 88.114% |
| CRISPR Therapeutics AG | 463.49 Million USD | 96.14% |
| Precision BioSciences, Inc. | 92.46 Million USD | 80.649% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 92.957% |
| Fortress Biotech, Inc. | 200.19 Million USD | 91.062% |
| Fortress Biotech, Inc. | 200.19 Million USD | 91.062% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 45.36% |
| ImmuCell Corporation | 9.61 Million USD | -86.044% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 88.662% |
| Immix Biopharma, Inc. | 16.14 Million USD | -10.851% |
| Incyte Corporation | 1.19 Billion USD | 98.497% |
| Innoviva, Inc. | 132.15 Million USD | 86.461% |
| IO Biotech, Inc. | 91.44 Million USD | 80.433% |
| Jaguar Health, Inc. | 42.01 Million USD | 57.414% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 89.43% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 78.781% |
| ContextLogic Inc. | 387 Million USD | 95.377% |
| MiMedx Group, Inc. | 229.72 Million USD | 92.211% |
| MEI Pharma, Inc. | 34.78 Million USD | 48.563% |
| NextCure, Inc. | 67.63 Million USD | 73.546% |
| Onconetix, Inc. | 34.9 Million USD | 48.743% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -40.377% |
| Opthea Limited | 191.96 Million USD | 90.679% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -550.262% |
| Vaxcyte, Inc. | 468.04 Million USD | 96.177% |
| PDS Biotechnology Corporation | 43.04 Million USD | 58.433% |
| Precigen, Inc. | 84.18 Million USD | 78.745% |
| Pharming Group N.V. | 225.49 Million USD | 92.065% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 89.339% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 75.343% |
| PureTech Health plc | 144.59 Million USD | 87.626% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 86.264% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 92.702% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 26.388% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 92.176% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 42.019% |
| Acelyrin, Inc. | 422.06 Million USD | 95.761% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -138666.178% |
| Summit Therapeutics Inc. | 87.68 Million USD | 79.595% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 51.725% |
| Senti Biosciences, Inc. | 94.7 Million USD | 81.107% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 85.518% |
| Elevation Oncology, Inc. | 45.44 Million USD | 60.628% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 39.284% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -353.889% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 86.463% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 47.506% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -111.721% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 90.131% |
| Seer, Inc. | 110.49 Million USD | 83.806% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 74.654% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 80.859% |
| ESSA Pharma Inc. | 32.13 Million USD | 44.319% |
| GlycoMimetics, Inc. | 39.28 Million USD | 54.455% |
| GT Biopharma, Inc. | 13.57 Million USD | -31.795% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 91.861% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 91.103% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 93.103% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 68.476% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 66.915% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -80.048% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 95.566% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 5.476% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 64.704% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 93.109% |
| Aptose Biosciences Inc. | 52.35 Million USD | 65.825% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -24.164% |
| Soligenix, Inc. | 7.79 Million USD | -129.531% |
| Century Therapeutics, Inc. | 56.07 Million USD | 68.09% |
| Kura Oncology, Inc. | 165.8 Million USD | 89.209% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 84.374% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -115.08% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -620.996% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 83.386% |
| Autolus Therapeutics plc | 196.72 Million USD | 90.905% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 78.865% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 84.635% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 7.69% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 94.439% |
| GRI Bio, Inc. | 11.33 Million USD | -57.922% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -153.589% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 86.362% |
| IGM Biosciences, Inc. | 265.59 Million USD | 93.263% |
| INmune Bio, Inc. | 29.89 Million USD | 40.151% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 89.631% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 55.617% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -11.973% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -13.664% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 71.187% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 83.359% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 93.51% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 94.065% |
| Verastem, Inc. | 92.08 Million USD | 80.569% |
| Abeona Therapeutics Inc. | 17.93 Million USD | 0.259% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 90.366% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 85.262% |
| Histogen Inc. | 14.27 Million USD | -25.368% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -11.493% |
| Surrozen, Inc. | 18.55 Million USD | 3.544% |
| Organovo Holdings, Inc. | 14.91 Million USD | -19.963% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -251.507% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 70.016% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 30.235% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 61.936% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -134.415% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 89.956% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 63.069% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 92.697% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -16.438% |
| Apollomics, Inc. | 54.14 Million USD | 66.951% |
| Amarin Corporation plc | 272.35 Million USD | 93.43% |
| Mesoblast Limited | 5.9 Million USD | -203.16% |
| Turnstone Biologics Corp. | 78.33 Million USD | 77.16% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 92.671% |
| Synaptogenix, Inc. | 8.31 Million USD | -115.213% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -22.669% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 92.929% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 46.317% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -102.605% |
| Exelixis, Inc. | 1.58 Billion USD | 98.872% |
| Better Therapeutics, Inc. | 38.26 Million USD | 53.237% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 92.289% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 97.908% |
| NLS Pharmaceutics AG | 11.8 Million USD | -51.541% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -122.491% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 40.344% |
| Gritstone bio, Inc. | 148.37 Million USD | 87.941% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 74.016% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -9.366% |
| Avid Bioservices, Inc. | 25.99 Million USD | 31.172% |
| Insmed Incorporated | 949.26 Million USD | 98.115% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -14.039% |
| MediWound Ltd. | 18.86 Million USD | 5.17% |
| OmniAb, Inc. | 83.89 Million USD | 78.673% |
| Alector, Inc. | 248.8 Million USD | 92.809% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 92.364% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 65.757% |
| Zai Lab Limited | 547.47 Million USD | 96.732% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 95.512% |
| Aura Biosciences, Inc. | 84.99 Million USD | 78.948% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 92.76% |
| Immunic, Inc. | 99.22 Million USD | 81.967% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 88.748% |
| Veracyte, Inc. | 357.93 Million USD | 95.001% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.802% |
| FibroGen, Inc. | 398.11 Million USD | 95.506% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -25.915% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -159.766% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -151.097% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.45% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 30.845% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 94.348% |
| TG Therapeutics, Inc. | 198.47 Million USD | 90.985% |
| Galecto, Inc. | 35.62 Million USD | 49.778% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 56.026% |
| Fortrea Holdings Inc. | 457.3 Million USD | 96.087% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 67.035% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 38.041% |
| XBiotech Inc. | 37.51 Million USD | 52.299% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 74.016% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 13.349% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 87.405% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 81.94% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 83.839% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 98.133% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 37.97% |
| Vaxxinity, Inc. | 56.05 Million USD | 68.078% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 95.845% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 19.794% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 83.861% |
| NexImmune, Inc. | 28.16 Million USD | 36.478% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -223.498% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.364% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 29.72% |
| Scopus BioPharma Inc. | 11.71 Million USD | -52.733% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 85.918% |
| Ainos, Inc. | 12.95 Million USD | -38.138% |
| Pluri Inc. | 22.48 Million USD | 20.407% |
| Prothena Corporation plc | 282.4 Million USD | 93.664% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 91.055% |
| Celularity Inc. | 215.05 Million USD | 91.68% |
| Rallybio Corporation | 78.93 Million USD | 77.332% |
| Cue Biopharma, Inc. | 19.54 Million USD | 8.441% |
| MeiraGTx Holdings plc | 151.07 Million USD | 88.157% |
| Omeros Corporation | 94.75 Million USD | 81.116% |
| Humacyte, Inc. | 23.49 Million USD | 23.852% |
| Immunocore Holdings plc | 308.04 Million USD | 94.191% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -427.803% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 79.402% |
| Blueprint Medicines Corporation | 722.86 Million USD | 97.525% |
| CalciMedica, Inc. | 21.81 Million USD | 17.988% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 76.035% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 88.855% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 89.555% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 93.934% |
| Pulmatrix, Inc. | 22.03 Million USD | 18.811% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 48.25% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 79.866% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 96.756% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 75.338% |
| Cytokinetics, Incorporated | 173.61 Million USD | 89.694% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 48.016% |
| Nutriband Inc. | 5.73 Million USD | -212.041% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 58.974% |
| Vor Biopharma Inc. | 126.03 Million USD | 85.804% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 98.495% |
| Evogene Ltd. | 27.79 Million USD | 35.615% |
| ProKidney Corp. | 151.52 Million USD | 88.191% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 75.878% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -132.605% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 97.087% |
| CorMedix Inc. | 48.95 Million USD | 63.453% |
| BioLineRx Ltd. | 50.8 Million USD | 64.78% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 88.127% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 53.003% |
| Atai Life Sciences N.V. | 125.78 Million USD | 85.775% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 78.083% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 78.021% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 92.915% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 45.35% |
| MediciNova, Inc. | 10.9 Million USD | -64.147% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 86.11% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -146.469% |
| GeoVax Labs, Inc. | 6.02 Million USD | -197.111% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 96.244% |
| Biomea Fusion, Inc. | 126.13 Million USD | 85.815% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 98.636% |
| Mereo BioPharma Group plc | 35.84 Million USD | 50.079% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 90.637% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 92.219% |
| Absci Corporation | 73.66 Million USD | 75.711% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 35.13% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 86.606% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 92.611% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 93.172% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 91.398% |
| Allakos Inc. | 196.05 Million USD | 90.874% |
| Imunon, Inc. | 20.31 Million USD | 11.905% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 84.231% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 95.146% |
| BioAtla, Inc. | 129.68 Million USD | 86.203% |
| NLS Pharmaceutics AG | 11.8 Million USD | -51.541% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -12.936% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 78.93% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 57.152% |
| XOMA Corporation | 46.46 Million USD | 61.491% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 83.905% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 87.441% |
| aTyr Pharma, Inc. | 12.97 Million USD | -37.857% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 82.739% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 89.65% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 92.977% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 52.169% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -117.543% |
| Akari Therapeutics, Plc | 16.8 Million USD | -6.465% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -686.84% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 94.022% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -165.912% |
| UroGen Pharma Ltd. | 138.88 Million USD | 87.117% |
| Sutro Biopharma, Inc. | 243 Million USD | 92.637% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -145.958% |
| Orgenesis Inc. | 45.75 Million USD | 60.897% |
| Entera Bio Ltd. | 8.86 Million USD | -101.947% |
| GH Research PLC | 41.22 Million USD | 56.595% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 30.401% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 78.457% |
| Xencor, Inc. | 306.97 Million USD | 94.171% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -262.666% |
| Replimune Group, Inc. | 234.77 Million USD | 92.379% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 12.676% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 90.671% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -165.912% |
| Portage Biotech Inc. | 18.19 Million USD | 1.684% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -146.469% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 82.953% |
| OncoCyte Corporation | 25.63 Million USD | 30.208% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -193.531% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -56.17% |
| Purple Biotech Ltd. | -22.46 Million USD | 179.639% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -8.571% |
| scPharmaceuticals Inc. | 65.17 Million USD | 72.548% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -111.677% |
| HilleVax, Inc. | 133.34 Million USD | 86.582% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -73.967% |
| Tharimmune, Inc. | 9.45 Million USD | -89.234% |
| Genprex, Inc. | 31.06 Million USD | 42.395% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 90.459% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 42.976% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -2238.89% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -228.489% |
| OKYO Pharma Limited | 8243.57 USD | -216948.087% |
| Savara Inc. | 15.74 Million USD | -13.639% |
| Curis, Inc. | 58.35 Million USD | 69.339% |
| Daré Bioscience, Inc. | 33.6 Million USD | 46.763% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -251.351% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -139.814% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 33.785% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.456% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 10.265% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 96.413% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 88.355% |
| Erasca, Inc. | 141.52 Million USD | 87.357% |
| bluebird bio, Inc. | 240.23 Million USD | 92.552% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -295.242% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 98.975% |
| DBV Technologies S.A. | 92.16 Million USD | 80.585% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -295.242% |
| Moderna, Inc. | 6.39 Billion USD | 99.72% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 58.008% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -24.548% |
| Molecular Templates, Inc. | 63.09 Million USD | 71.64% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 73.175% |
| Travere Therapeutics, Inc. | 472 Million USD | 96.209% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 87.515% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 71.179% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 58.786% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 91.403% |
| MacroGenics, Inc. | 217.21 Million USD | 91.763% |
| RenovoRx, Inc. | 11.39 Million USD | -57.007% |
| Adicet Bio, Inc. | 152.03 Million USD | 88.232% |
| Prime Medicine, Inc. | 186.63 Million USD | 90.413% |
| Aditxt, Inc. | 25.95 Million USD | 31.052% |
| Adagene Inc. | 41.83 Million USD | 57.227% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -144.764% |
| Quantum-Si incorporated | 111.65 Million USD | 83.976% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 89.588% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -22.738% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 50.052% |
| SciSparc Ltd. | 9.01 Million USD | -98.563% |
| Vericel Corporation | 142.04 Million USD | 87.403% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -106.691% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 22.505% |
| Generation Bio Co. | 144.46 Million USD | 87.615% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 78.451% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 79.305% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 93.95% |
| Invivyd, Inc. | 205.75 Million USD | 91.304% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 75.204% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -90.782% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 76.224% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -73.933% |
| 2seventy bio, Inc. | 289.88 Million USD | 93.828% |
| ADMA Biologics, Inc. | 66.58 Million USD | 73.129% |
| Clene Inc. | 41.07 Million USD | 56.437% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -39.699% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 67.347% |
| GeoVax Labs, Inc. | 6.02 Million USD | -197.111% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 94.918% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 51.289% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 46.951% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 82.746% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 45.096% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 89.492% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 97.669% |
| Evaxion Biotech A/S | 22.27 Million USD | 19.656% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 86.799% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 92.382% |
| Trevena, Inc. | 38.41 Million USD | 53.421% |
| Surrozen, Inc. | 18.55 Million USD | 3.544% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 77.619% |
| Cingulate Inc. | 22.75 Million USD | 21.383% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 338.822% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 59.942% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -117.302% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 82.554% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 97.627% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 71.176% |
| Clearmind Medicine Inc. | 8.74 Million USD | -104.688% |
| Kronos Bio, Inc. | 128.11 Million USD | 86.034% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 78.718% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -510.044% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 82.254% |
| Statera Biopharma, Inc. | 28.82 Million USD | 37.937% |
| ImmunityBio, Inc. | 362.87 Million USD | 95.069% |
| Korro Bio, Inc. | 84.53 Million USD | 78.834% |
| Kineta, Inc. | 21.15 Million USD | 15.426% |
| BioVie Inc. | 31.95 Million USD | 43.999% |
| Codexis, Inc. | 66.51 Million USD | 73.101% |
| Celularity Inc. | 215.05 Million USD | 91.68% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 92.105% |
| Celcuity Inc. | 66.23 Million USD | 72.984% |
| Virax Biolabs Group Limited | 6.54 Million USD | -173.291% |
| Cibus, Inc. | 320.3 Million USD | 94.414% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 58.39% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 47.132% |
| IN8bio, Inc. | 30.33 Million USD | 41.021% |
| Kodiak Sciences Inc. | 277.32 Million USD | 93.548% |
| Annexon, Inc. | 143.72 Million USD | 87.551% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 85.977% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 21.897% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -2695.705% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 97.705% |
| Eyenovia, Inc. | 25.4 Million USD | 29.575% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 87.248% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -221.692% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 77.389% |
| Arcellx, Inc. | 200.19 Million USD | 91.063% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 61.018% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 91.732% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -79.698% |
| Moolec Science SA | 52.75 Million USD | 66.081% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 70.734% |
| Geron Corporation | 70.44 Million USD | 74.599% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 61.555% |
| Royalty Pharma plc | 862.4 Million USD | 97.925% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 80.98% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -91.818% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 20.929% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 91.39% |
| Humacyte, Inc. | 23.49 Million USD | 23.852% |
| Structure Therapeutics Inc. | 102.77 Million USD | 82.591% |
| 89bio, Inc. | 151.2 Million USD | 88.167% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 77.671% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -23.057% |
| Genelux Corporation | 24.33 Million USD | 26.474% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 47.256% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 89.65% |
| Notable Labs, Ltd. | 14.77 Million USD | -21.141% |
| Liquidia Corporation | 87.98 Million USD | 79.664% |
| Mustang Bio, Inc. | 48.5 Million USD | 63.109% |
| Immunovant, Inc. | 282.7 Million USD | 93.671% |
| Quantum-Si incorporated | 111.65 Million USD | 83.976% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 20.633% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 15.867% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 82.46% |
| Acasti Pharma Inc. | 11.3 Million USD | -58.327% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 21.939% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -11.973% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 61.556% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -1477.016% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -12.631% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 38.634% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 56.765% |
| PepGen Inc. | 84.76 Million USD | 78.892% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 39.616% |
| United Therapeutics Corporation | 885.1 Million USD | 97.978% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 21.857% |
| Solid Biosciences Inc. | 104.31 Million USD | 82.848% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 45.326% |
| Immuneering Corporation | 58.41 Million USD | 69.369% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -251.507% |
| Silo Pharma, Inc. | 3.92 Million USD | -356.226% |
| Belite Bio, Inc | 31.66 Million USD | 43.5% |
| XOMA Corporation | 46.46 Million USD | 61.491% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 73.512% |
| Bionomics Limited | 17.89 Billion USD | 99.9% |
| Apogee Therapeutics, Inc. | 93 Million USD | 80.761% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 150.147% |
| uniQure N.V. | 285.08 Million USD | 93.724% |
| Cassava Sciences, Inc. | 105.95 Million USD | 83.113% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -144.764% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 90.787% |
| Forte Biosciences, Inc. | 32.47 Million USD | 44.907% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -115.345% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 39.131% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -221.692% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -25.915% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -101.288% |
| Altimmune, Inc. | 30.55 Million USD | 41.444% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 95.816% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 150.147% |
| Compugen Ltd. | 43.97 Million USD | 59.308% |
| Peak Bio, Inc. | 1249.13 USD | -1432297.829% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 75.86% |
| Benitec Biopharma Inc. | 22.38 Million USD | 20.058% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 92.643% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 37.314% |
| Zura Bio Limited | 62.63 Million USD | 71.435% |
| PolyPid Ltd. | 21.04 Million USD | 14.98% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -9.932% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 37.314% |
| Instil Bio, Inc. | 85.78 Million USD | 79.143% |
| argenx SE | 1.53 Billion USD | 98.833% |
| Immunome, Inc. | 122.82 Million USD | 85.432% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 63.088% |
| Verona Pharma plc | 67.15 Million USD | 73.355% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 30.877% |
| Shattuck Labs, Inc. | 93.61 Million USD | 80.887% |
| CervoMed Inc. | 14.95 Million USD | -19.62% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 74.693% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -109.416% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 64.917% |
| Moolec Science SA | 52.75 Million USD | 66.081% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -8.779% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 86.502% |
| AnaptysBio, Inc. | 181.56 Million USD | 90.146% |
| Design Therapeutics, Inc. | 78.19 Million USD | 77.117% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 79.444% |
| NeurAxis, Inc. | 8.82 Million USD | -102.835% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -42.173% |
| Lumos Pharma, Inc. | 38.66 Million USD | 53.724% |
| Achilles Therapeutics plc | 75.25 Million USD | 76.224% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 30.877% |
| 180 Life Sciences Corp. | 13.47 Million USD | -32.758% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 32.487% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -510.044% |
| Nutriband Inc. | 5.73 Million USD | -212.041% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 83.849% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 67.85% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 64.833% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 72.931% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 66.941% |
| Palisade Bio, Inc. | 13.32 Million USD | -34.328% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 60.597% |
| Beam Therapeutics Inc. | 554.19 Million USD | 96.771% |
| Neurogene Inc. | 55.58 Million USD | 67.809% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 92.799% |
| AEON Biopharma, Inc. | 48.42 Million USD | 63.054% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 81.499% |
| Sesen Bio, Inc. | 78.38 Million USD | 77.172% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 78.579% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -42.152% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 96.033% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 79.642% |
| Athira Pharma, Inc. | 125.46 Million USD | 85.739% |
| Vaccinex, Inc. | 23.45 Million USD | 23.716% |
| HCW Biologics Inc. | 21.02 Million USD | 14.909% |
| XOMA Corporation | 46.46 Million USD | 61.491% |
| Nektar Therapeutics | 190.9 Million USD | 90.627% |
| Arvinas, Inc. | 480 Million USD | 96.272% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -686.84% |
| Merus N.V. | 200.49 Million USD | 91.076% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 82.688% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 48.317% |
| Rezolute, Inc. | 70.38 Million USD | 74.58% |
| Clene Inc. | 41.07 Million USD | 56.437% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -9.244% |
| BeyondSpring Inc. | 24.86 Million USD | 28.041% |
| Synlogic, Inc. | 58.53 Million USD | 69.431% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -0.003% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -298.319% |
| Peak Bio, Inc. | 1249.13 USD | -1432297.829% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 70.399% |
| Krystal Biotech, Inc. | 160.42 Million USD | 88.847% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 93.389% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 94.859% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -729.611% |
| MannKind Corporation | 125.59 Million USD | 85.754% |
| Ikena Oncology, Inc. | 84.57 Million USD | 78.845% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -85.472% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 80.031% |
| Gossamer Bio, Inc. | 183.75 Million USD | 90.263% |
| CohBar, Inc. | 12.38 Million USD | -44.431% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 64.726% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 35.13% |
| Legend Biotech Corporation | 583.14 Million USD | 96.932% |
| Mural Oncology plc | 192.07 Million USD | 90.684% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 73.353% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -10.822% |
| Disc Medicine, Inc. | 91.12 Million USD | 80.365% |
| Champions Oncology, Inc. | 28.11 Million USD | 36.348% |
| REGENXBIO Inc. | 321.15 Million USD | 94.429% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -233.739% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 67.909% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 54.075% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 84.354% |
| Vaxart, Inc. | 90.72 Million USD | 80.279% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -110.006% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 58.189% |
| Cellectis S.A. | 97.32 Million USD | 81.615% |
| Longeveron Inc. | 21.25 Million USD | 15.8% |
| Repare Therapeutics Inc. | 167.35 Million USD | 89.309% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 98.685% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 76.347% |
| Revolution Medicines, Inc. | 498.76 Million USD | 96.413% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -168.979% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 59.293% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 76.012% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 74.305% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -61.777% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.625% |
| Denali Therapeutics Inc. | 527.23 Million USD | 96.606% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -106.691% |
| Veru Inc. | 101.34 Million USD | 82.345% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 23.559% |
| Cingulate Inc. | 22.75 Million USD | 21.383% |
| Passage Bio, Inc. | 108.38 Million USD | 83.492% |
| Context Therapeutics Inc. | 25.07 Million USD | 28.637% |
| Exicure, Inc. | 14.07 Million USD | -27.114% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 91.317% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 58.679% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -94.965% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 92.913% |
| Nuvalent, Inc. | 149.49 Million USD | 88.031% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -121.802% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 82.738% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 16.581% |
| OmniAb, Inc. | 83.89 Million USD | 78.673% |
| Anew Medical, Inc. | 1.3 Million USD | -1275.457% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 45.39% |
| Lipocine Inc. | 15.08 Million USD | -18.65% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 73.885% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 76.504% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 55.617% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 84.42% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 20.066% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 97.306% |
| Ocugen, Inc. | 71.56 Million USD | 74.999% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 80.938% |
| Q32 Bio Inc. | 92.68 Million USD | 80.694% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 15.498% |
| Alumis Inc. Common Stock | 158.17 Million USD | 88.688% |
| Equillium, Inc. | 50.6 Million USD | 64.643% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 71.329% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -28.672% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 5.156% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 61.891% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 83.504% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -44.379% |
| Dominari Holdings Inc. | 23.83 Million USD | 24.932% |
| Edesa Biotech, Inc. | 9.22 Million USD | -94.004% |
| vTv Therapeutics Inc. | 11.9 Million USD | -50.269% |
| Bio-Techne Corporation | 563.03 Million USD | 96.822% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 95.623% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 93.342% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 86.473% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -24.159% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 89.07% |
| Nkarta, Inc. | 131.65 Million USD | 86.409% |
| BioCardia, Inc. | 12.12 Million USD | -47.616% |
| Iterum Therapeutics plc | 47.46 Million USD | 62.306% |